Mechanistically, TTC36-high HCC cells exhibit profound compensatory PI3K/Akt hyperactivation, enabling HCC cells to bypass Ras/MAPK dependency and rendering them less sensitive to sorafenib. The gene discussed is AKT1; the disease is hepatocellular carcinoma.